Leiomyosarcoma Clinical Trial
Official title:
Detection of Circulating Tumor Cells in Patients With Metastatic Sarcomas
The sarcomas represent 1% of all cancers in adults, 8% in adolescents and young people, and
10% in children. Even though it is a rare cancer, it contributes to a significant loss of
years of life in comparison with other types of cancer, due the fact that it affects children
and young people. The diagnosis and treatment are difficult, considering the diversity and
rarity of this disease. In addition, on average, more than 50% of patients with high-grade
sarcoma present tumor relapse and distant recurrence is considered the main cause of death.
The presence of Circulating Tumor Cells (CTCs) in the blood of patients with sarcoma may be
an early marker of tumor invasion, because it is known that the CTCs circulate in the blood
for months or years before the development of metastases. The CTCs can be used to monitor the
response of the tumor to treatment, in order to match time, dose, and type of therapy.
Objectives: collect blood from patients with different types of sarcoma (leiomyosarcoma,
synovial sarcoma, pleomorphic sarcoma and liposarcoma) in order to isolate and quantify CTCs.
The investigators also have an intention to identify genes of resistance to treatment in
these cells.
Methodology: This is a prospective study, to be made by whole blood collection from 40
patients with different types of sarcomas (leiomyosarcoma, pleomorphic sarcoma, synovial
sarcoma and liposarcoma). The collections will be made in three different moments: before the
beginning of the treatment, during and at the end of this (8 mL). Blood samples will be
processed and filtered on ISET system for the isolation and quantification of CTCs. Later, it
will be performed immunocytochemistry (ICQ) single and/or double staining for protein
assessment. The following proteins will be assessed: CD45, MRP1, MRP2 and MRP7.
Expected Results: The investigators hope that this study can show if the CTCs can be used as
"liquid biopsy" in patients with leiomyosarcoma, synovium and pleomorphic sarcoma and
liposarcoma.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04535271 -
Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma
|
Phase 2 | |
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06088290 -
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
| Terminated |
NCT02940041 -
Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal Malignant Tumors
|
||
| Completed |
NCT01442662 -
Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine
|
Phase 2 | |
| Completed |
NCT00062868 -
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04214457 -
Development of a Predictive Model for Early Differential Diagnosis of Uterine Leiomyomas and Leiomyosarcomas
|
||
| Active, not recruiting |
NCT04420975 -
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
|
Phase 1 | |
| Terminated |
NCT04099277 -
A Study of LY3435151 in Participants With Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT05548179 -
Exploring Clinical Trial Experiences of People With Leiomyosarcoma
|
||
| Completed |
NCT00093080 -
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
|
Phase 2 | |
| Active, not recruiting |
NCT04624178 -
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
|
Phase 2 | |
| Terminated |
NCT03959033 -
Patient Reported Outcome Measures (PROMs) With Trabectedin
|
||
| Recruiting |
NCT02275286 -
Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01956084 -
Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma
|
Phase 1 | |
| Completed |
NCT01426633 -
Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas
|
Phase 1 | |
| Completed |
NCT00400569 -
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
|
Phase 2 | |
| Recruiting |
NCT05080790 -
Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma
|
Phase 2 | |
| Active, not recruiting |
NCT05269355 -
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
|
Phase 2/Phase 3 |